CORC

在结果中检索

CORC

浏览/检索结果: 共33条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：48/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：40/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：33/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：31/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：13/0  |  提交时间：2019/12/05
On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy 会议论文
作者:  Wei, Lai;  Shang, Jia;  Xie, Qing;  Jia, Zhansheng;  Gao, Pujun
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Convex Combination for Source Localization Using Received Signal Strength Measurements 会议论文
作者:  Wang, Qi;  Duan, Zhansheng;  Li, X. Rong;  Hanebeck, Uwe D.
收藏  |  浏览/下载：10/0  |  提交时间：2019/11/19
On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy 会议论文
作者:  Wei, Lai;  Shang, Jia;  Xie, Qing;  Jia, Zhansheng;  Gao, Pujun
收藏  |  浏览/下载：9/0  |  提交时间：2019/11/19
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：12/0  |  提交时间：2019/11/19

©版权所有 ©2017 CSpace - Powered by CSpace